ROCKVILLE, Md., March 21, 2013 /PRNewswire/ -- OriGene Technologies, Inc., a leading genome wide product company for research and diagnostic applications, announced the completion of a $21.3 million Series C financing led by Qiming Venture Partners and Kleiner Perkins Caufield Byers China. OriGene's previous investor IDG-Accel also participated in this round. "We are pleased with the high level of commitment and enthusiasm from our new and existing investors. We intend to use the net proceeds from this financing to advance our growth strategy and operations," said Wei-Wu He, Ph.D., OriGene's Chairman and Chief Executive Officer. (Logo - http://photos.prnewswire.com/prnh/20130107/DC38100LOGO) About OriGene Technologies OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide. OriGene has developed an extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which offers significant improvement over traditional antibodies. UltraMAB™ antibodies are validated by OriGene's proprietary high density microarray technology for a wide variety of antibody applications. For more information, visit www.origene.com. SOURCE OriGene Technologies, Inc.